What is the optimal management of potentially resectable stage III-N2 NSCLC? Results of a fixed-effects network meta-analysis and economic modelling.
Matthew EvisonRoss MaconachieToby MercerCaitlin H DalyNicky J WeltonShahzeena AslamDoug WestNeal NavaniPublished in: ERJ open research (2023)
CRS provides an extended time in a disease-free state leading to improved cost-effectiveness over CR and CS in potentially resectable stage III-N2 NSCLC.